companies / biminibiotech-nl
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-06 json
| total_raised | 3,456,0003.5M | ○ |
|---|---|---|
| founded | 2019 | |
| hq | Leiden, Netherlands | |
| industry | unknown | |
| stage | seed |
Develops first-in-class small-molecule WASp modulators, including agonist BM-011 and antagonist programs. Targets patients with AML, lymphomas, leukemias and autoimmune conditions like arthritis and colitis. Dual agonist-and-antagonist platform unlocks WASp biology, licensed in from Switzerland's Institute of Oncology Research.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-01 | seed | 3,240,0003.2M | null | ○ |
PHP 7.4.33, WordPress 6.5.8, Apache HTTP Server, Mesmerize Companion 1.6.149, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, ExtendThemes Mesmerize, Varnish, MySQL, jquery 3.7.1, apache
| fact | status | src |
|---|---|---|
| Seed, $3.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |